C. STOCKHOLDERS EQUITY (Details) - USD ($)	3 Months Ended						9 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Jun. 30, 2019	Jun. 30, 2018
Common Stock
Beginning balance	$ 299,517	$ 278,435	$ 280,346	$ 166,246	$ 132,581	$ 119,031	$ 280,346	$ 119,031
Beginning balance, shares	29,951,628	27,843,327	28,034,487	16,624,552	13,258,051	11,903,133	28,034,487	11,903,133
Sale of common stock					$ 25,011	$ 12,895
Sale of common stock, shares					2,501,145	1,289,478
Warrant exercises	$ 40,141	$ 15,239	$ 2,987	$ 11,177
Warrant exercises, shares	4,014,109	1,523,933	298,682	1,117,644
401(k) contributions paid in common stock	$ 43	$ 104	$ 123	$ 399	$ 259	$ 190
401(k) contributions paid in common stock, shares	4,339	10,419	12,279	39,862	25,901	18,984
Stock issued to nonemployees for service	$ 208	$ 774	$ 628	$ 816	$ 1,241	$ 137
Stock issued to nonemployees for service, shares	20,825	77,449	62,784	81,604	124,082	13,705
Conversion of notes payable and interest to common stock				$ 11,068	$ 554
Conversion of notes payable and interest to common stock, shares				1,106,806	55,373
Shares issued (returned) for settlement of clinical research costs		$ 5,000	$ (5,649)	$ 6,000	$ 6,600
Shares issued (returned) for settlement of clinical research costs, shares		500,000	(564,905)	600,000	660,000
Equity based compensation - employees	$ (40)	$ (35)
Equity based compensation - employees, shares	(4,000)	(3,500)
Option exercises	$ 428
Option exercises, shares	42,770
Purchase of stock by officers and directors	$ 372
Purchase of stock by officers and directors, shares	37,243
Ending balance	$ 340,669	$ 299,517	$ 278,435	$ 195,706	$ 166,246	$ 132,581	$ 340,669	$ 195,706
Ending balance, shares	34,066,914	29,951,628	27,843,327	19,570,468	16,624,552	13,258,051	34,066,914	19,570,468
Additional Paid-In Capital
Beginning balance	$ 337,449,398	$ 332,775,129	$ 331,312,184	$ 307,425,853	$ 300,975,618	$ 296,298,401	$ 331,312,184	$ 296,298,401
Sale of common stock					4,652,130	2,437,105
Warrant exercises	10,212,680	2,640,395	646,766	2,906,619
401(k) contributions paid in common stock	36,318	36,779	35,118	36,274	36,261	35,690
Stock issued to nonemployees for service	140,062	224,855	201,752	208,387	227,254	25,270
Conversion of notes payable and interest to common stock				2,179,648	108,746
Shares issued (returned) for settlement of clinical research costs		1,285,000	5,649	1,704,000	1,240,800
Equity based compensation - employees	1,521,861	530,865	573,660	465,487	279,817	1,448,098
Option exercises	96,862
Purchase of stock by officers and directors	234,625
Stock issuance cost	(8,010)	(43,625)			(94,773)
Warrants issued with notes payable				291,234
Ending balance	349,683,796	337,449,398	332,775,129	315,217,502	307,425,853	300,975,618	349,683,796	315,217,502
Accumulated Deficit
Beginning balance	(336,793,393)	(330,345,712)	(331,591,614)	(310,650,374)	(305,942,239)	(299,754,409)	(331,591,614)	(299,754,409)
Warrant exercises				0
Net income (loss)	(12,084,768)	(6,447,681)	1,245,902	(6,014,568)	(4,708,135)	(6,187,830)
Ending balance	(348,878,161)	(336,793,393)	(330,345,712)	(316,664,942)	(310,650,374)	(305,942,239)	(348,878,161)	(316,664,942)
Beginning balance	955,522	2,707,852	916	(3,058,275)	(4,834,040)	(3,336,977)	916	(3,336,977)
Sale of common stock					4,667,141	2,450,000
Warrant exercises	10,252,821	2,655,634	649,753	2,917,796
401(k) contributions paid in common stock	36,361	36,883	35,241	36,673	36,520	35,880	108,485	109,073
Stock issued to nonemployees for service	140,270	225,629	202,380	209,203	228,495	25,407
Conversion of notes payable and interest to common stock				2,190,716	109,300
Shares issued (returned) for settlement of clinical research costs		1,290,000	0	1,710,000	1,247,400
Equity based compensation - employees	1,521,821	530,830	573,660	465,487	279,817	1,448,098
Option exercises	97,290
Purchase of stock by officers and directors	234,997
Stock issuance cost	(8,010)	(43,625)			(94,773)
Warrants issued with notes payable				291,234
Net income (loss)	(12,084,768)	(6,447,681)	1,245,902	(6,014,568)	(4,708,135)	(6,187,830)	(17,286,547)	(16,910,533)
Ending balance	$ 1,146,304	$ 955,522	$ 2,707,852	$ (1,251,734)	$ (3,058,275)	$ (4,834,040)	$ 1,146,304	$ (1,251,734)